Kissei

Rigel has agreements with Kissei to develop and commercialize TAVALISSE (fostamatinib disodium hexahydrate) and REZLIDHIA (olutasidenib) in Japan and other specified Asian countries.

TAVALISSE

  • Rigel has an exclusive license and supply agreement with Kissei to develop and commercialize TAVALISSE in all potential indications in Japan, China, Taiwan and the Republic of Korea.
  • In April 2023, Kissei announced the availability of TAVALISSE for the treatment of adult chronic ITP in Japan.
  • Kissei announced that its licensing partner in South Korea, JW Pharmaceutical Corporation, had obtained marketing authorization for Tavalisse for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment in January 2025.
  • Rigel exclusively supplies Kissei product and receives tiered transfer price payments based on net sales of the product in the territory.

REZLIDHIA

  • Kissei expanded their relationship with Rigel to include REZLIDHIA in September 2024. Kissei gained exclusive rights to develop and commercialize olutasidenib in all current and potential indications in Japan, the Republic of Korea and Taiwan
  • Rigel received an upfront cash payment, and is eligible for development, regulatory and commercial milestone payments. Rigel will also receive product transfer price payments based on tiered net sales for the exclusive supply of REZLIDHIA.